Page 32 - Michael Erman News Today

Three organizations on Wednesday said they were suing the US government to block enforcement of a program that gives Medicare the power to negotiate drug prices.

NEW YORK, June 21 (Reuters) - The Pharmaceutical Research and Manufacturers of America (PhRMA) on Wednesday said it was suing the U.S. government to block enforcement of a program that gives Medicare the power to negotiate drug prices. ...

NEW YORK, June 21 (Reuters) - The Pharmaceutical Research and Manufacturers of America (PhRMA), the leading industry lobby group, and two other organizations on Wednesday said they were suing the U.S. governmen...

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that adults aged 60 and above may receive the recently approved vaccines from Pfizer and GSK to prevent severe res...

NEW YORK (Reuters) - The Pharmaceutical Research and Manufacturers of America (PhRMA) on Wednesday said it was suing the U.S. government to block enfo...

Advisers to the U.S. Food and Drug Administration on Thursday unanimously backed the use of updated COVID-19 vaccines that would target an XBB Omicron subvariant of the coronavirus for the 2023-2024 vaccination campaign. The panel voted 21-0 in favor XBB-tailored shots.

Advisers to the U.S. Food and Drug Administration on Thursday will discuss and vote on whether to recommend targeting one of the currently dominant XBB coronavirus variants in updated COVID-19 shots being developed for a fall vaccination campaign. FDA staff reviewers in documents released this week said available evidence suggests this year's shots should target an XBB variant. XBB and its offshoots, which now account for most U.S. infections, are descendents of the Omicron variant that ...

Advisers to the U.S. Food and Drug Administration on Thursday unanimously backed the use of updated COVID-19 vaccines that would target an XBB Omicron subvariant of the coronavirus for the 2023-2024... | June 15, 2023

-Advisers to the U.S. Food and Drug Administration were meeting on Thursday to discuss and vote on whether to recommend targeting one of the currently dominant XBB coronavirus variants in updated... | June 16, 2023

The spokesperson confirmed the details from an interview with Soros published in The Wall Street Journal on Sunday. A hedge fund manager turned philanthropist and major backer of liberal causes, Soros, 92, said he previously didn't want his Open Society Foundations (OSF) to be taken over by one of his five children.